Aethlon Medical to Present at The Salk Institute

March 12, 2010

SAN DIEGO, March 12 /PRNewswire-FirstCall/ — Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced that Richard H. Tullis, Ph.D., the company’s Chief Science Officer, will present at the French Biotech Tour held at The Salk Institute in La Jolla, California, on March 15, 2010.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

The French Biotech Tour is a showcase of the most innovative technologies and solutions developed by Californian and French biotech companies to tackle infectious diseases and to improve patients’ quality of life.

About Aethlon Medical

Aethlon Medical, Inc. creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our lead product, the HemopurifierÃ‚® is the first-in-class medical device to selectively capture circulating viruses and immunosuppressive proteins prior to cell and organ infection. Human studies have documented the ability of our HemopurifierÃ‚® to reduce viral load in patients infected with Hepatitis-C virus (HCV) and the Human Immunodeficiency Virus (HIV). Our primary clinical and commercialization focus is to establish the HemopurifierÃ‚® as an adjunct therapy to enhance and prolong the benefit of traditional infectious disease drug regimens.

The HemopurifierÃ‚® is also a broad-spectrum treatment candidate against drug resistant bioterror and pandemic threats. Third party research institutes have verified the capability of the device to capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) was formed in October of 2009 to leverage attributes of the HemopurifierÃ‚® in the emerging exosome research field. ESI seeks to inhibit the immune cell destruction caused by exosomes secreted by solid tumors, lymphomas, and leukemia. At present, the capture of immunosuppressive exosomes secreted from ovarian cancer tumors has been demonstrated invitro. The preservation of anti-cancer immune cells would likely improve patient responsiveness to established treatment options, including immunotherapy and chemotherapy. ESI is also analyzing exosome-related opportunities to improve early cancer detection and post-surgery surveillance of tumor growth, as well as approaches to harvest exosomes for research purposes and potential reintroduction into patients afflicted with autoimmune conditions such as Rheumatoid Arthritis and Lupus.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the HemopurifierÃ‚® to reduce viral loads and other disease conditions or to identify disease conditions such ascancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.